Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279755 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by ProJenX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 4
- Study locations
NCT05279755: Recruiting Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by ProJenX.
NCT05279755 is a Phase 1 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by ProJenX. The registered enrollment target is 72 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279755, a Phase 1 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by ProJenX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.
Conditions Studied
Interventions
- DRUG placebo
- DRUG prosetin
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Worldwide Clinical Trials Early Phase Services - San Antonio
Quebec
- The Neuro - Montréal Neurological Institute-Hospital - Montreal
Utrecht
- University Medical Center Utrecht - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-02-26 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
What NCT05279755 shows while recruiting
NCT05279755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT05279755 reports a single indexed study location in Massachusetts, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT05279755 about?
NCT05279755 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS". The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.
What is the current status of trial NCT05279755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-02-26. Estimated completion is 2026-10-31.
What conditions does trial NCT05279755 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05279755?
The interventions under investigation include: placebo (DRUG), prosetin (DRUG).
Who is sponsoring clinical trial NCT05279755?
This trial is sponsored by ProJenX, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279755 being conducted?
This trial has 4 study locations across Massachusetts, Texas, Quebec, Utrecht. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05279755's enrollment target sits among peer trials
72 50th of 102 higher than 52 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
Regulatory T Cells for Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI